The firm faced criticism after a report revealed that consultants had discussed destroying documents related to the opioid business and proposed that a drugmaker pay its distributors rebates for overdoses.
The firm faced criticism after a report revealed that consultants had discussed destroying documents related to the opioid business and proposed that a drugmaker pay its distributors rebates for overdoses.